TD Waterhouse Canada Inc. Purchases 24,477 Shares of Astrazeneca Plc $AZN

TD Waterhouse Canada Inc. increased its position in shares of Astrazeneca Plc (NYSE:AZN) by 623.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 28,401 shares of the company’s stock after acquiring an additional 24,477 shares during the quarter. TD Waterhouse Canada Inc.’s holdings in Astrazeneca were worth $2,611,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of AZN. Brighton Jones LLC raised its stake in shares of Astrazeneca by 93.2% during the 4th quarter. Brighton Jones LLC now owns 5,782 shares of the company’s stock worth $379,000 after acquiring an additional 2,789 shares in the last quarter. AQR Capital Management LLC raised its stake in shares of Astrazeneca by 45.3% during the 1st quarter. AQR Capital Management LLC now owns 37,501 shares of the company’s stock worth $2,756,000 after acquiring an additional 11,690 shares in the last quarter. Amundi raised its stake in shares of Astrazeneca by 54.4% during the 2nd quarter. Amundi now owns 10,274 shares of the company’s stock worth $731,000 after acquiring an additional 3,618 shares in the last quarter. Jump Financial LLC raised its stake in shares of Astrazeneca by 898.4% during the 2nd quarter. Jump Financial LLC now owns 33,478 shares of the company’s stock worth $2,339,000 after acquiring an additional 30,125 shares in the last quarter. Finally, Daiwa Securities Group Inc. raised its stake in shares of Astrazeneca by 1.2% during the 2nd quarter. Daiwa Securities Group Inc. now owns 46,642 shares of the company’s stock worth $3,259,000 after acquiring an additional 559 shares in the last quarter. Institutional investors own 20.35% of the company’s stock.

Astrazeneca Stock Performance

Shares of Astrazeneca stock opened at $194.99 on Thursday. The company has a current ratio of 0.94, a quick ratio of 0.72 and a debt-to-equity ratio of 0.51. Astrazeneca Plc has a 12-month low of $132.32 and a 12-month high of $212.71. The company has a market cap of $302.42 billion, a price-to-earnings ratio of 33.59, a P/E/G ratio of 1.47 and a beta of 0.35.

Astrazeneca Announces Dividend

The business also recently declared a dividend, which was paid on Monday, March 23rd. Shareholders of record on Friday, February 20th were paid a dividend of $1.595 per share. The ex-dividend date was Friday, February 20th. This represents a yield of 156.0%. Astrazeneca’s dividend payout ratio is presently 74.83%.

Analysts Set New Price Targets

Several research analysts recently commented on AZN shares. Wall Street Zen lowered shares of Astrazeneca from a “buy” rating to a “hold” rating in a research note on Saturday, April 4th. Barclays reiterated an “overweight” rating on shares of Astrazeneca in a research note on Tuesday, January 6th. Morgan Stanley reiterated an “overweight” rating on shares of Astrazeneca in a research note on Wednesday, April 8th. Citigroup assumed coverage on shares of Astrazeneca in a research note on Tuesday, January 27th. They set a “buy” rating on the stock. Finally, TD Cowen restated a “buy” rating on shares of Astrazeneca in a research note on Wednesday, March 18th. Eight research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $102.67.

More Astrazeneca News

Here are the key news stories impacting Astrazeneca this week:

• Positive Sentiment: Late?stage Ultomiris data met the primary endpoint in IgA nephropathy (IgAN), showing a statistically significant reduction in proteinuria — a clinical signal that supports potential accelerated approvals and expands the drug’s addressable rare?kidney market. AstraZeneca’s Ultomiris reduces urine protein in late-stage trial of rare kidney disease
• Positive Sentiment: Tozorakimab recorded a third consecutive Phase III win in COPD, prompting Citi to raise its conviction in the drug’s blockbuster potential and model a path toward roughly $5bn peak sales — a meaningful upside case for long?term revenue growth. AstraZeneca’s tozorakimab treble puts $5bn sales ceiling in sight, says Citi
• Neutral Sentiment: Analysts are reassessing valuation after mixed short?term momentum: the stock has delivered strong 1?year returns but recent price action is softer, leaving investors to balance impressive clinical progress with an already sizable market cap. Assessing AstraZeneca (LSE:AZN) Valuation As Strong 1?Year Returns Contrast With Softer Recent Momentum
• Negative Sentiment: Regulatory/payer risk: AZN’s CEO warned that Germany’s cost?containment plans risk limiting patient access to new drugs the company plans to launch — a reminder that pricing and reimbursement policies in major markets could blunt upside from recent clinical wins. Germany risks missing out on new drugs, AstraZeneca CEO tells paper

Astrazeneca Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.